Effect of Estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation
article
OA: green
CC0
⤵ 3 in-corpus citations
Abstract
In the menopausal transition (MT), combined oral contraceptive (COC) should be chosen accordingly to its neutrality on liver metabolism and to its ability to counter the increase of fat mass (FM) that occurs in this reproductive period of life. This prospective multi-centric observational study was conducted on 36 women in their MT at the Universities of Cagliari, Modena and Naples. The body weight (BW), the Body Mass Index (BMI), the waist to hip ratio (WHR), the measurement of body composition (BC) with the Multi-frequency Bioelectrical Impedance (MF-BIA) were performed before, at the 6th and at the 12th month of the study in which a group of women (control group; N.18) did not assume COC, whereas the other 18 women assumed the four-phasic COC containing estradiol valerate (EV) associated with dienogest (EV/DNG group). In comparison to controls in the EV/DNG group, a significant decrease (p < 0.05) of BW (58.8 ± 7.6 to 57.3 ± 7.0), BMI (24.1 ± 2.7 to 23.5 ± 2.8), WHR (0.82 ± 0.052 to 0.79 ± 0.048) and FM (17.7 ± 5.4 to 16.4 ± 5.6) was observed. In controls, FM significantly increased (17.0 ± 11 to 17.7 ± 2.7; p < 0.05). In conclusion, these results suggest that the anti-androgenic and progestinic activities of DNG associated with a weak estrogenic activity of EV, is a contraceptive method capable of counteracting the negative changes of BC occurring in the MT.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (43)
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest via openalex
- Pharmacokinetics of Estradiol Valerate 2mg + Dienogest 2mg (Climodien?? 2/2) after Single and Repeated Oral Administration in Healthy Postmenopausal Women via openalex
- Review of clinical experience with estradiol in combined oral contraceptives via openalex
- The pharmacological profile of dienogest via openalex
- doi:10.1016/0039-128x(96)00007-4 via openalex
- doi:10.1097/01.gme.0000174469.37198.a0 via openalex
- doi:10.1111/j.1445-5994.1971.tb02272.x via openalex
- doi:10.1007/s11154-011-9182-4 via openalex
- doi:10.1111/j.1467-789x.2009.00592.x via openalex
- doi:10.1038/oby.2005.173 via openalex
- doi:10.1016/j.fertnstert.2010.02.015 via openalex
- doi:10.1034/j.1600-0412.2002.810705.x via openalex
- doi:10.1016/j.mce.2009.08.018 via openalex
- doi:10.1111/j.1471-0528.1970.tb03447.x via openalex
- doi:10.1210/jc.85.8.2832 via openalex
- doi:10.1016/j.clnu.2004.09.012 via openalex
- doi:10.1111/j.1471-0528.1970.tb03467.x via openalex
- doi:10.1016/j.tem.2015.06.003 via openalex
- doi:10.1007/s00592-003-0066-2 via openalex
- doi:10.1080/j.1600-0412.2002.810705.x via openalex
- doi:10.2307/20168137 via openalex
- doi:10.1016/s0015-0282(97)00242-2 via openalex
- doi:10.1001/jama.292.24.2991 via openalex
- doi:10.1038/ijo.2008.25 via openalex
- doi:10.1016/j.contraception.2008.08.007 via openalex
- doi:10.3275/8943 via openalex
- doi:10.1097/gme.0b013e318240f6f3 via openalex
- doi:10.1152/jappl.2000.88.5.1643 via openalex
- doi:10.1093/humrep/14.4.893 via openalex
- doi:10.1002/14651858.cd003987.pub3 via openalex
- doi:10.3109/09513590.2014.922947 via openalex
- doi:10.1210/jc.2002-021839 via openalex
- doi:10.1210/jc.2003-030328 via openalex
- doi:10.1080/13697130802416640 via openalex
- doi:10.3109/13697139909025561 via openalex
- doi:10.1007/bf03401300 via openalex
- doi:10.1097/gme.0b013e318174ea4d via openalex
- doi:10.1016/j.fertnstert.2007.01.039 via openalex
- doi:10.1016/j.contraception.2012.07.008 via openalex
- doi:10.1016/j.maturitas.2012.01.018 via openalex
- doi:10.1210/jcem.85.8.6740 via openalex
- doi:10.1152/jappl.1999.87.3.1087 via openalex
Cited by (3)
- Effect of combined oral contraceptives with estrogen identical to natural estrogen on the metabolic profile and body composition in females during the menopausal transition 2023
- Needs, expectations and doubt users of hormonal contraceptives 2020
- Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest 2019
Source provenance
- openalex
- last seen: 2026-05-11T07:04:57.594281+00:00
License: CC0
· commercial use OK